Menu Close

We strive to relieve patients from the burdens of epilepsy and pain.

Our Therapeutic Focus


A spectrum disorder characterized by recurring, unprovoked seizures.

Chronic Pain

Chronic pain with a significant CNS component such as fibromyalgia and neuropathic pain are difficult to treat.

Lead Candidate for Epilepsy: NCT10004

NeuroCycle Therapeutics is developing its lead candidate, NCT10004, as a first-in-class, orally administered treatment for refractory epilepsy. NCT10004 decreases seizures in traditional and genetic seizure models.

NeuroCycle Therapeutics, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule drugs that target the central nervous system.

Our goal is to maximize the humanitarian impact and commercial potential of our innovative technology by targeting both common, highly prevalent disorders with large unmet medical needs, and orphan indications neglected by large pharmaceutical companies. This approach has tremendous potential to bring positive change to our world and impact patients’ lives.